Spring 2027
Posted on 9/7/2026
Integrated health system delivering patient-centered care
No salary listed
Houston, TX, USA + 5 more
More locations: The Woodlands, TX, USA | Cypress, TX, USA | Pearland, TX, USA | Sugar Land, TX, USA | Katy, TX, USA
In Person
Applicants must specify a preferred unit and location. External applicants generally require a BSN; ADN applicants are accepted at Northeast, Pearland, and Southeast.
Bachelor's, Associate's
See people who can refer or advise you
Memorial Hermann Health System is a nonprofit, community-owned health system serving the Greater Houston area with more than 260 care delivery sites. It delivers safe, high-quality, patient-centered care through an integrated network that combines clinical expertise with advanced technology. The system differentiates itself through its community ownership, value-driven culture, and broad network of hospitals, clinics, and specialty services. Its goal is to improve regional health outcomes by providing comprehensive, accessible care and leveraging innovation to personalize treatment.
Company Size
10,001+
Company Stage
Grant
Total Funding
$5M
Headquarters
Houston, Texas
Founded
1907
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Wellness Program
Mental Health Support
Memorial Hermann earns top AHA awards for exceptional stroke care. Memorial Hermann Katy Hospital, 23900 Katy Freeway in Katy, is one of ten of the health system's acute care hospitals receiving the American Heart Association's "Get With The Guidelines(R)- Stroke Gold Plus Quality Achievement Award," recognizing their commitment to providing care that follows the latest, research-backed treatment guidelines proven to save lives and reduce disability after stroke. CONTRIBUTED PHOTO Posted Friday, August 28, 2026 5:29 pm CONTRIBUTED REPORT Memorial Hermann has once again been nationally recognized by the American Heart Association (AHA) for delivering fast, evidence-based stroke care that gives patients the best chance at recovery, the hospital system announced on August 18. Ten of the health system's acute care hospitals received the AHA'S "Get With The Guidelines(R)- Stroke Gold Plus Quality Achievement Award," recognizing their commitment to providing care that follows the latest, research-backed treatment guidelines proven to save lives and reduce disability after stroke. The hospitals included: · Memorial Hermann Cypress Hospital · Memorial Hermann Greater Heights Hospital · Memorial Hermann Katy Hospital · Memorial Hermann Memorial City Medical Center · Memorial Hermann Pearland Hospital · Memorial Hermann Southeast Hospital · Memorial Hermann Southwest Hospital · Memorial Hermann Sugar Land Hospital · Memorial Hermann-Texas Medical Center · Memorial Hermann The Woodlands Medical Center Adding to this year's honors, Memorial Hermann Southeast Hospital advanced from the Silver to Gold Plus award, while Memorial Hermann Southwest Hospital earned the "Target: StrokeSM Honor Roll Advanced Therapy" award for the first time, recognizing their ability to quickly deliver advanced treatment to patients experiencing certain types of stroke. "Stroke is a medical emergency and every second matters," said Memorial Hermann's System Stroke Program Director Sandi Shaw. "It's an honor to have the American Heart Association recognize the incredible work happening across our hospitals every day to ensure patients receive the right treatment as quickly as possible. These awards are a testament to the teamwork of our emergency physicians, neurologists, nurses, EMS partners and countless others who work together to improve outcomes for our patients." In addition to AHA "Get With The Guidelines," the following campuses received the AHA's Target: StrokeSM awards for meeting specific criteria that reduces the time between an eligible patient's arrival at the hospital and treatment with thrombolytic therapy. Target: StrokeSM Honor Roll Elite Plus was awarded to: · Memorial Hermann Memorial City Medical Center · Memorial Hermann Southwest Hospital · Memorial Hermann-Texas Medical Center · Memorial Hermann The Woodlands Medical Center Target: StrokeSM Honor Roll Elite was awarded to: · Memorial Hermann Cypress Hospital · Memorial Hermann Greater Heights Hospital · Memorial Hermann Katy Hospital · Memorial Hermann Sugar Land Hospital · Memorial Hermann Pearland Hospital Target: StrokeSM Honor Roll was awarded to: · Memorial Hermann Southeast Hospital Target: StrokeSM Honor Roll Advanced Therapy was awarded to: · Memorial Hermann The Woodlands Medical Center · Memorial Hermann Southwest Hospital Finally, nine campuses were also recognized with the AHA's Target: Type 2 Diabetes(TM) Honor Roll award that aims to offer patients with type 2 diabetes, who might be at higher risk for complications, the most up-to-date, evidence-based care when hospitalized due to stroke. These campuses included: · Memorial Hermann Cypress Hospital · Memorial Hermann Greater Heights Hospital · Memorial Hermann Katy Hospital · Memorial Hermann Pearland Hospital · Memorial Hermann Southeast Hospital · Memorial Hermann Southwest Hospital · Memorial Hermann Sugar Land Hospital · Memorial Hermann-Texas Medical Center · Memorial Hermann The Woodlands Medical Center For more information about Memorial Hermann's award-winning stroke care, visit www.memorialhermann.org/services/treatments/stroke-treatment or call 713-222-CARE (2273). Other items that may interest you
Memorial Hermann Health System has made a strategic investment in PartsSource, a Cleveland-based clinical technology performance platform. The investment aims to strengthen healthcare technology infrastructure across more than 1,600 hospitals using PartsSource's system. PartsSource provides an enterprise platform that unifies parts, service, contracts, asset intelligence, and workforce capacity for healthcare technology management. The platform currently services over 15,000 clinical sites across the US, using 25 years of data to deliver real-time visibility and predictive insights. Memorial Hermann joins 150 other health systems using PartsSource's platform, which helps hospitals transition from reactive maintenance to proactive, data-driven asset management. The system enables faster parts sourcing, higher first-time fix rates, and standardised enterprise workflows for clinical engineering teams.
Former Houston transplant surgeon's federal case moves toward trial. By Megan Reyna - KHOU 11 Aug 19, 2026 Preview this article 1 min Dr. John Stevenson Bynon, 66, the former surgical director of liver transplantation at Memorial Hermann, is accused of falsifying medical records. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4
Helix secures AstraZeneca partnership to power drug discovery with US genomic data. July 8, 2026 AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The deal gives AstraZeneca (Nasdaq: AZN) access to Helix's continuously growing, deeply phenotyped cohorts spanning cardiometabolic, respiratory, and autoimmune disease areas. The agreement is AstraZeneca's latest move in a systematic multi-source genomics strategy and arrives as Helix establishes itself as a recurring platform partner to top-tier pharma. Financial terms were not disclosed. GenoSphere cohorts combine Exome+ genomic sequencing with longitudinal electronic health record data averaging 13 years of follow-up per patient, drawn from the Helix Research Network - described by the company as the largest precision health network in North America. The datasets are de-identified and fully consented, with the option to launch targeted follow-on studies. The platform is designed to support target identification, disease biology research, and patient stratification across the drug development lifecycle, functioning as a discovery infrastructure layer rather than a single-indication tool. Helix recently launched its Genomic Advantage program with Nebraska Medicine and Memorial Hermann Health System, adding new health system partners that feed the underlying research network. For AstraZeneca, the Helix deal adds a commercially managed, US-based, exome-sequenced cohort to a genomics portfolio that already includes co-funded access to the UK Biobank whole-genome sequencing dataset and membership in the Alliance for Genomic Discovery - a consortium that includes AbbVie, Amgen, GSK, Merck, and Novo Nordisk, among others. AstraZeneca's Centre for Genomics Research has publicly stated a goal of analyzing 2 million genomes by 2026. The Helix agreement adds a North American commercial data layer to AstraZeneca's existing European biobank partnerships. Helix previously signed a multi-year collaboration with GSK, announced in January 2026 using an identical structural template, with AstraZeneca now the third major pharma to sign onto the same GenoSphere platform following Helix's March 2026 agreement with Alnylam Pharmaceuticals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Cadence, the clinical AI company managing chronic care for older adults, announced a $100 million Series C, amid adoption of its AI-powered care model across...